{"id":153393,"date":"2026-11-16T09:32:45","date_gmt":"2026-11-16T00:32:45","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4888-20261116-01_wp_executive_change\/"},"modified":"2026-11-16T09:32:45","modified_gmt":"2026-11-16T00:32:45","slug":"4888-20261116-01_wp_executive_change","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/","title":{"rendered":"Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma"},"content":{"rendered":"<p>The BNCT pharmaceutical Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL, indicated for recurrent meningioma, has received partial revision approval to its marketing authorization. This is the first approval in Japan for an indication targeting recurrent meningioma. The company promotes indication expansion as a core growth strategy. National health insurance coverage is scheduled for March 1, 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stella Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4888-20261116-01.pdf","jir_short_summary":"The BNCT pharmaceutical Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL, indicated for recurrent meningioma, has received partial revision approval to its marketing authorization. This is the first approval in Japan for an indication targeting recurrent meningioma. The company promotes indication expansion as a core growth strategy. National health insurance coverage is scheduled for March 1, 2027.","jir_summary":"### Summary of Approval\nToday, we obtained partial revision approval to the marketing authorization for the BNCT pharmaceutical Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL to include \"recurrent meningioma\" in its indications or efficacy. This approval represents an expansion of the indication to recurrent meningioma and is the first such case in Japan.\n\n### Strategy and Outlook\nThe company is advancing its BNCT business based on three pillars: \"indication expansion,\" \"expansion of treatment facilities,\" and \"overseas expansion.\" This approval is an important result for indication expansion and is expected to broaden the range of treatable patients. The company will proceed with related procedures aiming for insurance coverage on March 1, 2027, and after approval, coordination between regulatory measures and insurance through evaluation-based medical care is anticipated.","jir_financial_highlights":"Planned Insurance Coverage Date: 2027-03-01 (Unknown)","jir_category":"","jir_hashtags":"#RecurrentMeningioma, BNCT, #IndicationExpansion, #TreatmentFacilityExpansion","jir_key_figures":"Indication expansion approval for recurrent meningioma (new indication)\nPlanned start of insurance coverage: 2027-03-01\nMedium- to long-term growth expectations from expanded BNCT treatment indications","jir_meta_title":"Stella Pharma Corporation: Approval for BNCT Indication Expansion to Recurrent Meningioma | November 2026","jir_meta_description":"Stella Pharma Corporation has obtained partial revision approval to the marketing authorization for Stevoronin, a BNCT drug, expanding its indication to recurrent meningioma\u2014the first such approval in Japan. Insurance coverage is planned to start on March 1, 2027. Watch for developments as this aligns with the company's growth strategy.","jir_og_title":"Stella Pharma Corporation: Approval for BNCT Indication Expansion to Recurrent Meningioma | November 2026","jir_og_description":"The BNCT therapeutic Stevoronin has received approval for expanded indication to recurrent meningioma. Insurance coverage is scheduled to begin on March 1, 2027. Future developments warrant attention.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-153393","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/\",\"name\":\"Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-16T00:32:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/","url":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/","name":"Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-16T00:32:45+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261116-01_wp_executive_change\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin\u00ae Intravenous Infusion Bag 9000mg\/300mL for BNCT Indicated for Recurrent Meningioma"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59263","title":"STELLA PHARMA CORPORATION","ticker":"4888"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/153393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=153393"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/153393\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=153393"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=153393"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=153393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}